Germany's Stratec 2025  prelim revenue falls 2.6%, misses estimates

Stratec SE

25/03/2026 18:54

Overview

Germany diagnostics systems maker's preliminary 2025 revenue fell 2.6% yr/yr, missing analyst expectations

Company posted adjusted EBIT margin of 10.0% after €10.5 mln impairments on Diatron assets

Outlook

Stratec expects 2026 constant-currency sales growth in a medium to high single-digit percentage range

Company expects 2026 adjusted EBIT margin at around the previous year's level

Stratec sees sales growth mainly in H2 2026, with Q1 expected to see a sharp reduction in sales and a dip in profitability

Result Drivers

IMPAIRMENTS - €10.5 mln impairments on intangible assets and inventories related to delayed market launch and decreased sales potential for Diatron product family

ROBUST DEMAND - Strong demand for immunoassay and immunohematology systems and slight recovery in molecular diagnostics supported outlook

RISING INPUT COSTS - Benefits of scale expected to be offset by higher input costs due to geopolitical conflicts

Company press release: ID:nEQ5wFRJBa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
EUR 250.90 mln
EUR 257.76 mln (7 Analysts)

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)